Solid Cancer

CuraGen and TopoTarget Present New Clinical Results with Belinostat at the Annual Meeting in ASCO and at the conference "2007 Pan Pacific Lymphoma"

Published in Drug Law Weekly, May 8th, 2007

TopoTarget A/S (CSE: TOPO) and CuraGen Corporation (NASDAQ: CRGN) announced today that preliminary interim clinical data on belinostat (PXD101), a histone deacetylase (HDAC) inhibitor being investigated for the treatment of cancer, are expected to be presented at two upcoming major medical meetings.

One oral and one poster presentation discussing interim clinical results with belinostat will be made at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being hosted in Chicago, IL, June 2-5, 2007.

A poster presentation will also be made at the 2007 Pan Pacific Lymphoma Conference, which is being hosted on the Island of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Law Weekly

Source: Drug Law Weekly (2007-05-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry